Emedgene
AI-based Platform for Automated Genomic Interpretation
Company Overview
Snapshot
Founded in April 2015 by Einat Metzer, Shay Tzur, and Niv Mizrahi, Emedgene operated with 11–50 employees. The company was acquired by Illumina in December 2021, marking a significant exit in the Health Tech & Life Sciences sector.
Business overview
Emedgene developed a genomics intelligence platform that leverages natural language processing to analyze new genetic publications and integrate them into an continuously updated knowledge base. The platform then applies machine-learning algorithms to identify pathogenic variants, providing a clear pathway for clinical decisions. Serving clinical labs and research organizations, Emedgene aimed to enhance dry lab efficiency, reduce interpretation and reporting times, increase yield, and scale genomic interpretation operations. The company operated within the Health Tech & Life Sciences sector, focusing on areas like precision medicine, diagnostics, and digital healthcare.
Strategic signal
In December 2020, Emedgene collaborated with Illumina to scale the interpretation of genomic data for rare diseases. This partnership highlighted Emedgene's technological capabilities and strategic alignment with a major player in the genomics industry, signaling strong validation of its AI-driven approach to genomic analysis and its potential for broader market impact prior to its acquisition.
Log in to access full profile ›Company Intelligence Q&A
- What was Emedgene's exit event?
- Emedgene was acquired by Illumina in December 2021. This acquisition led to the company's inactive status.
- What was a key collaboration for Emedgene?
- In December 2020, Emedgene collaborated with Illumina to scale the interpretation of genomic data, particularly for rare diseases.
- What was Emedgene's contribution to rare disease patients?
- In February 2020, Emedgene donated appraisals for undiagnosed rare disease patients to the Rare Genomics Institute and other organizations.